Recombinant Human Thyrotropin receptor (TSHR)-VLPs (Active)

^{In
Stock}

品名簡稱：

Recombinant Human TSHR protein-VLPs (Active)
貨號：

CSB-MP025131HU
說明書：

MSDS Datasheet
規(guī)格：

￥5250
圖片：
CSB-MP025131HU is detected by Mouse anti-6*His monoclonal antibody.

Activity
Measured by its binding ability in a functional ELISA. Immobilized Human TSHR at 10 μg/ml can bind Anti-TSHR recombinant antibody (CSB-RA025131MA1HU). The EC₅₀ is 30.81-36.12 ng/mL.The VLPs (CSB-MP3838) is negative control. Biological Activity Assay

The purity of VLPs was greater than 90% as determined by SEC-HPLC
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 90% as determined by SEC-HPLC.
生物活性：

Measured by its binding ability in a functional ELISA. Immobilized Human TSHR at 10 μg/mL can bind Anti-TSHR recombinant antibody (CSB-RA025131MA1HU). The EC50 is 30.81-36.12 ng/mL.The VLPs (CSB-MP3838) is negative control.
基因名：

TSHR
Uniprot No.：

P16473
別名：

Thyrotropin receptor; Thyroid-stimulating hormone receptor (TSH-R)
種屬：

Homo sapiens (Human)
蛋白長度：

Full Length of Mature Protein
來源：

Mammalian cell
分子量：

86.0 kDa
表達(dá)區(qū)域：

21-764aa
氨基酸序列

GMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLIETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPDALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETLTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTALPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLMCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQEDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIVVWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSEYYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACAIMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCCYVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSKILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL
蛋白標(biāo)簽：

C-terminal 10xHis-tagged(This tag can be tested only under denaturing conditions)
產(chǎn)品提供形式：

Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4
復(fù)溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項(xiàng)：

The VLPs are expressed from human 293 cells (HEK293).Mix the sample gently by repeatedly pipetting it up and down. Do not vortex.Repeated freezing and thawing is not recommended.Store the protein at -20℃/-80℃ upon receiving it, and ensure to avoid repeated freezing and thawing, otherwise, it will affect the protein activity. The immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Datasheet & COA：

Please contact us to get it.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Receptor for the thyroid-stimulating hormone (TSH) or thyrotropin. Also acts as a receptor for the heterodimeric glycoprotein hormone (GPHA2:GPHB5) or thyrostimulin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Plays a central role in controlling thyroid cell metabolism.
基因功能參考文獻(xiàn)：
1. MCT8 and TSHR form heteromers. PMID: 29290039
2. TSHR mutations occur in approximately 5% thyroid nodules in a large consecutive series with indeterminate cytology. TSHR mutations may be associated with an increased cancer risk when present at high allelic frequency PMID: 29516685
3. This work is devoted to the ascertainment of serological cross-reactivity between OmpF porin from Yersinia pseudotuberculosis (YpOmpF) and human thyroid-stimulating hormone receptor (hTSHR). PMID: 29079441
4. Genetic polymorphisms of CTLA-4 gene on the nucleotide 49 at codon 17 of exon 1, TSHR gene SNP rs2268458 of intron 1, number of regulatory T cells and TRAb levels play a role as risk factors for relapse in patients with Graves' disease. PMID: 29093229
5. Overexpression of TSHR was found in a great majority of hepatocellular carcinomatissues and associated with unfavorable prognosis PMID: 29715101
6. Signaling dissection using diverse inhibitors indicated that EOC cell proliferation driven by thyrostimulin-TSHR signaling is PKA independent, but does require the involvement of the MEK-ERK and PI3K-AKT signal cascades, which are activated mainly via the trans-activation of EGFR PMID: 27273257
7. SNPs rs179247 and rs12101255 were significantly associated with Graves disease. rs12101255 and rs2268458 polymorphisms had no association with Graves diseases and Graves ophthalmopathy. PMID: 27456991
8. Among the evaluated TSHR gene SNPs, the rs4411444 GG genotype and the rs4903961 C allele in the enhancer regions of the TSHR gene were most strongly associated with the development of Graves disease, especially intractable disease, and that of Hashimoto disease, respectively. PMID: 27762730
9. Low expression of TSHR is associated with dilated cardiomyopathy and impaired left ventricular function accompanied by increased risk of death. PMID: 29320567
10. Monoallelic TSHR mutations are significantly associated with positive newborn screen for congenital hypothyroidism, and the association is further strengthened by the coexistence of monoallelic DUOX2 mutations. PMID: 29092890
11. The role of TSH Receptor cleavage into subunits and shedding of the A-Subunit in Graves' disease pathogenesis is reviewed. PMID: 27454362
12. a hot-spot mutation in EZH1 is the second most frequent genetic alteration in autonomous thyroid adenomas; the association between EZH1 and TSHR mutations suggests a 2-hit model for the pathogenesis of these tumors, whereby constitutive activation of the cAMP pathway and EZH1 mutations cooperate to induce the hyperproliferation of thyroid cells PMID: 27500488
13. Germline mutation in the thyrotropin receptor gene is associated with non-autoimmune hyperthyroidism. PMID: 28195550
14. Congenital Hypothyroidism With Gland-in-Situ 59% attributable to mutations in TSHR. PMID: 27525530
15. data support the association that low intrathymic TSHR expression is associated with susceptibility to developing pathogenic TSHR antibodies, while high intrathymic TSHR expression is protective PMID: 28099999
16. Graves' disease is associated with polymorphisms of TSHR intron 1 rs179247 and rs12101255. There is no association between rs179247 SNPs and Graves' ophthalmopathy PMID: 27465319
17. TSHR gene mutations p.R528C and c.392+4del4 associated with congenital hypothyroidism. PMID: 26864598
18. this study shows that the TSHR is not main factor contributing to determining common genetic basis among Graves disease and alopecia areata PMID: 27810496
19. TSHR D727E polymorphism might be involved in the pathogenesis of toxic multinodular goiter PMID: 27525921
20. lncRNA PVT1 may contribute to tumorigenesis of thyroid cancer through recruiting EZH2 and regulating TSHR expression. PMID: 26427660
21. experimentally verified contact of Ser-281 (ECD) and Ile-486 (TMD) was subsequently utilized in docking homology models of the ECD and the TMD to create a full-length model of a glycoprotein hormone receptor PMID: 27129207
22. TSHR gene polymorphisms are associated with typical symptoms in primary congenital hypothyroidism. PMID: 26356361
23. The eminent ratio of TSHr methylation in well-differentiated thyroid carcinoma against benign thyroidal nodules adduced that TSHr methylation status can be utilized as a tumor marker for well-differentiated thyroid cancer. PMID: 26519197
24. Thyroid-stimulating hormone receptor intronic polymorphisms are associated with the susceptibility to Graves' disease and Graves' ophthalmopathy in the Brazilian population, but do not appear to influence the disease course. PMID: 25543543
25. data support a structural model of the TSHR transmembrane domain with a bulged transmembrane helix TM2 and a straight TM5 that is specific of glycoprotein hormone receptors PMID: 26545118
26. TSHR gene variants are associated with congenital hypothyroidism. PMID: 25153578
27. the hinge region and its adjacent domains have roles in binding and signaling patterns of the thyrotropin and follitropin receptor PMID: 25340405
28. subclinical hypothyroidism in heterozygotes with TSHR mutations is a stable compensated condition with an appropriately adjusted set point for pituitary-thyroid feedback that does not require replacement therapy PMID: 25557138
29. Patients with preoperative TSHR-mRNA >/=1.02 ng/mug may be at a greater risk for recurrence of thyroid cancer. PMID: 26212344
30. The present study demonstrates that the SmartAmp2 method is useful to detect the R450H mutation in TSHR. PMID: 24895636
31. The aim of this study was to investigate whether chimeric TSH receptor based bioassay can predict Graves' disease remission/relapse after antithyroid drug PMID: 24968734
32. TSHR polymorphisms were not associated with the dose of T4 or central obesity among hypothyroid patients. PMID: 25079464
33. TSHR mutations are common among Hungarian patients with Congenital hypothyroidism. The novel genetic alterations revealed an important structural role of the N432(1.50) and the P449(2.39) residues in receptor expression and signaling, respectively. PMID: 25978107
34. c.317+1G>A splice site mutation in the TSHR gene leads to sever congenital hypothyroidism PMID: 24859513
35. Our data suggest a role for PTCSC2, FOXE1, and TSHR in the predisposition to papillary thyroid carcinoma. PMID: 25303483
36. germline polymorphisms of TSHR do not confer susceptibility for the development of autonomously functioning thyroid nodules. PMID: 24789540
37. our study showed a high implication of TSHR gene methylation and its significant association with BRAF V600E mutation in thyroid tumors, depicting a positive connection between TSHR pathway and MAP Kinase pathway. PMID: 24927793
38. Allele A of the rs179247 polymorphism in the TSHR gene is associated with lower risk of GO in young GD patients. PMID: 25061884
39. study reports a large deletion of the TSHR gene in two siblings with congenital hypothyroidism coming from a consanguineous Turkish family PMID: 24690939
40. A gain-of-function mutation (M435R) activates the Gs/adenylyl cyclase pathway, deactivates the Gq/11-phospholipase C pathway, and causes nonautoimmune hyperthyroidism in a Japanese family. PMID: 24608569
41. This review covers several mutations in TSHR which are clearly associated with a hyperthyroidism-phenotype, but interestingly show a lack of constitutive activity determined by in vitro characterization. PMID: 24845969
42. A nonsense thyrotropin receptor gene mutation is associated with congenital hypothyroidism and heart defects. PMID: 24945425
43. A newly discovered TSHR mutation L665F in transmembrane helix 7 of the receptor was detected in six members of a family with hyperthyroidism. PMID: 24947036
44. findings demonstrate TSH-R expression is thymus-specific within the immune system; data support the notion of a novel neuroendocrine-immune interaction in which TSH-R signaling in the thymus, most likely mediated by TSH, enhances thymic T-cell development PMID: 24635198
45. Autonomous adenomas are caused by somatic mutations of the thyroid-stimulating hormone receptor in children. PMID: 24480816
46. genetic association studies in population in Japan: Data suggest that patients with TSHR mutations exhibit persistent hyperthyroidism throughout follow-up; in such patients, hyperthyroidism progresses despite treatment with antithyroid drugs. PMID: 24279482
47. Significant reduction in TSHR messenger RNA is associated with ovarian carcinomas. PMID: 24844218
48. discovered a genetic-epigenetic interaction involving a noncoding SNP in the TSHR gene that regulates thymic TSHR gene expression and facilitates escape of TSHR-reactive T cells from central tolerance, triggering Graves disease PMID: 25122677
49. The expression of TSHR and NIS genes is differently controlled by multiple mechanisms, including epigenetic events elicited by major signaling pathways involved in thyroid tumorigenesis. PMID: 24353283
50. Only the IL1RN tandem repeats polymorphism may be associated with Hashimoto's thyroiditis susceptibility; TSHR and IL1RN polymorphisms may represent prognostic factors for predicting the severity of the disease. PMID: 24328419
顯示更多

收起更多
相關(guān)疾病：

Hypothyroidism, congenital, non-goitrous, 1 (CHNG1); Familial gestational hyperthyroidism (HTFG); Hyperthyroidism, non-autoimmune (HTNA)
亞細(xì)胞定位：

Cell membrane; Multi-pass membrane protein. Basolateral cell membrane; Multi-pass membrane protein.
蛋白家族：

G-protein coupled receptor 1 family, FSH/LSH/TSH subfamily
組織特異性：

Expressed in thyroide cells (at protein level). Expressed in the thyroid.
數(shù)據(jù)庫鏈接：

HGNC: 12373

OMIM: 275200

KEGG: hsa:7253

STRING: 9606.ENSP00000298171

UniGene: Hs.160411